Ribomunyl is oral vaccine, which forms immune reaction to 4 most often and common agents of airway infections.
Mode of action:
Has immunomodulatory effects, is riboksomalno-proteoglycan complex containing a part of the most common respiratory pathogens and ENT diseases. It has the ability to activate both humoral and cellular immunity. Ribosomes are a part of Ribomunyl contain antigens that are identical to the bacterial surface antigens, so getting into the body, stimulates the production of specific antibodies to these microorganisms (so-called effect of oral vaccine). This is due Ribomunyl ribosomal antigen able to stimulate the synthesis of antibodies specific to Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae. Proteoglycans membranes activate nonspecific immunity, resulting in enhanced phagocytic activity of polynuclear leukocytes and macrophages, increased activity of the factors of resistance of the organism (non-specific).
Ribomunyl stimulates the functional activity of B-and T-lymphocyte fusion of secretory and serum immunoglobulins (IgA), interleukin-1 alpha and gamma interferons. This is a preventive immunological effect of the drug (in relation to respiratory infections caused by viruses). Through the use of Ribomunyl in the complex therapy can significantly increase the effectiveness of treatment, to reduce the duration and reduce the need to use antibiotics and bronchodilators, and increase the duration of remitting period.
Indications for use:
Ribomunil used as a preventive and therapeutic agent in patients 6 months of life in protracted and recurrent infections of upper respiratory tract (rhinitis, otitis media, sinusitis, laryngitis, tonsillitis, pharyngitis) and respiratory tract infections (tracheitis, chronic bronchitis, bronchial asthma, infectious-dependent , pneumonia).
Ribomunil used in the prevention of infections (including recurrent) in patients belonging to risk groups (often ill, chronically ill, with chronic illnesses of upper respiratory tract, bronchial asthma and chronic bronchitis, before the start of the autumn and winter season, including the elderly and children 6 months of life).
How to use:
Ribomunil appointed inside, on an empty stomach in the morning. Regardless of age, a single dose patient is Ribomunyl - 1 tablet (one dose - 0.75 mg) or 3 tablets (with 1/3 doses - 0.25 mg) or the contents of one sachet dissolved in boiled water. During the first three weeks of therapy Ribomunil take the first four days of the week, and during the next five months - the first four days of each month.
It is recommended that twice a year, three-month preventive therapy courses, or once a year - six-month course.
For young children it is advisable to use Ribomunil in pellets.
When you receive Ribomunyl can rarely be observed: at the beginning of therapy - transient salivation, vomiting, nausea, diarrhea, allergic reactions (angioedema, urticaria). These symptoms are usually not expressed and not require discontinuation of therapy.
Ribomunil contraindicated in hypersensitivity to the drug, in autoimmune diseases. Be wary appoint Ribomunil in periarteritis nodosa and patients with HIV infection.
Special clinical efficacy and safety of the drug during pregnancy and lactation has not been. Appointment Ribomunyl pregnant and nursing should be made only after careful evaluation of the weighted ratio of benefit for the woman and the potential risk for the baby.
Interactions with other drugs:
Ribomunil can be combined with other drugs. Not been reported adverse drug interactions.
There are no data on overdose Ribomunyl.
Ribomunil tablets 0.75 mg, biconvex, round, odorless, white.
On 4 pieces, 1 blister in a cardboard box.
Ribomunil tablets 0.25 mg, biconvex, round, odorless, white.
12 pieces in blister, 1 blister in a cardboard box.
Granules for solution, odorless, white.
0.75 g polyethylene bag 1 (or laminated paper or aluminum foil).
On 4 bags in a carton box.
The drug is transported and stored at a temperature of 15-25 degrees Celsius.
Ribomunil granulate Bronhomunal.
Ribomunyl 0.75 mg tablet contains:
0.75 mg bacterial ribosomes (including ribosomes Haemophilus influenzae - 0,5 proportion, Streptococcus pyogenes - 3,0 proportion, Klebsiella pneumoniae - 3,5 proportion, Streptococcus pneumoniae - 3,0 parts), membrane proteinglikany 1,125 mg.
Other ingredients: magnesium stearate - 6 mg sorbitol - up to 294 mg of silicon - 1.5 mg.
Ribomunyl 0.25 mg tablet contains:
0.25 mg of the bacterial ribosome, membrane proteinglikany 0,275 mg.
Other ingredients: magnesium stearate - 2 mg silicon - 0.5 mg sorbitol - up to 98.4 mg.
Granules for solution include:
The ribosomal fraction of 0.75 mg, 1.125 mg of membrane proteinglikany.
Other Components: D-mannitol - 500 mg polyvidone - 10 mg.
In appointing Ribomunyl advisable to warn patients of a possible transient increase in body temperature for two to three days (a manifestation of the therapeutic effect). This symptom does not require discontinuation of therapy. In some cases, may cause transient mild symptoms of upper respiratory tract infections.
Package of 12 tablets.